AHR Relative Valuation
AHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AHR is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AHR's competitors is 5.85, providing a benchmark for relative valuation. American Healthcare REIT Inc Corp (AHR) exhibits a P/S ratio of 2.51, which is -57.09% above the industry average. Given its robust revenue growth of 12.47%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
CRGY
Crescent Energy Co
9.130
USD
-0.65%
CBZ
CBIZ Inc
74.130
USD
+1.60%
VRRM
Verra Mobility Corp
23.720
USD
+0.13%
GBTG
Global Business Travel Group Inc
6.090
USD
+0.33%
PAGP
Plains GP Holdings LP
18.410
USD
-0.16%
NWL
Newell Brands Inc
5.900
USD
-1.17%
ST
Sensata Technologies Holding PLC
27.170
USD
-0.55%
VRNA
Verona Pharma PLC
71.310
USD
+2.56%
KRYS
Krystal Biotech Inc
130.600
USD
+0.21%
BKH
Black Hills Corp
58.490
USD
-0.31%
FAQ
Is American Healthcare REIT Inc (AHR) currently overvalued or undervalued?
American Healthcare REIT Inc (AHR) is now in the Fair zone, suggesting that its current forward PE ratio of 75.55 is considered Fairly compared with the five-year average of 1.52. The fair price of American Healthcare REIT Inc (AHR) is between 29.70 to 42.77 according to relative valuation methord.
What is American Healthcare REIT Inc (AHR) fair value?
How does AHR's valuation metrics compare to the industry average?
What is the current P/B ratio for American Healthcare REIT Inc (AHR) as of May 19 2025?
What is the current FCF Yield for American Healthcare REIT Inc (AHR) as of May 19 2025?
What is the current Forward P/E ratio for American Healthcare REIT Inc (AHR) as of May 19 2025?